Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug.
In patients with spondyloarthritis, genetics and disease activity levels likely impact the composition of gut microbiota, according to data published in Arthritis & Rheumatology.
Major Advance in the Treatment of Axial Spondyloarthritis Coming medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.